Biological basis of anemia

Seminars in Oncology

Volumn 28, Issue 2 SUPPL. 8, 2001, Pages 1-6

  Bron, Dominique ^a   Meuleman, Natalie ^a   Mascaux, Cecile ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANEMIA; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SURVIVAL; CELL DIFFERENTIATION; CHRONIC DISEASE; HEMOLYSIS; HUMAN; HYPERSPLENISM; NUTRITIONAL DEFICIENCY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; STEM CELL; TISSUE OXYGENATION;

EID: 0034994237     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2001.25389     Document Type: Article

References (36)

1. Anaemia in cancer: Pathophysiology and treatment
2. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice
3. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study
4. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial
5. Erythropoietin therapy in cancer patients
6. Expression of the erythropoietin gene
7. Anemia induces accumulation of erythropoietin mRNA in the kidney and liver
8. Erythropoietin
9. Correction of anaemia of chronic renal failure with recombinant human erythropoietin: Safety and efficacy of one year's treatment in a European multicentre study of 150 haemodialysis-dependent patients
10. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin
11. The use of recombinant human erythropoietin in the correction of anemia in predialysis patients and its effect on renal function: A double-blind, placebo-controlled trial
12. Experience with epoetin alfa and acquired immunodeficiency syndrome anemia
13. A new era in blood conservation
14. Application of recombinant human erythropoietin in oncology
15. Recombinant erythropoietin therapy in cancer patients
16. Erythropoietin for anaemia in cancer patients
17. Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors
18. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life similar to three-times weekly dosing
19. Decreased erythropoietin response in patients with the anemia of cancer
20. Pathophysiology of cancer-related anemia
21. The application of recombinant human erythropoietin in anemic patients with cancer
22. In vivo suppression of erythropoiesis by tumor necrosis factor-alpha (TNF-alpha): Reversal with exogenous erythropoietin (EPO)
23. Plasma erythropoietin concentrations in patients receiving intensive platinum or nonplatinum chemotherapy
24. An analysis of potential factors allowing an individual prediction of cisplatin-induced anaemia
25. Chemotherapy-induced anemia in adults: Incidence and treatment
26. Cisplatin-associated anemia: An erythropoietin deficiency syndrome
27. Management of chemotherapy-induced anemia in solid tumors
28. The blood in systemic disorders
29. Hematopoiesis and cytokines. Relevance to cancer and aging
30. Pathogenesis of the anemia of chronic disease: A cytokine-mediated anemia
31. The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: Synergism of tumor necrosis factor and interferon-gamma
32. Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation
33. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production
34. The role of interleukin 1, erythropoietin, and red cell bound immunoglobulins in the anaemia of rheumatoid arthritis
35. Cachectin/tumor necrosis factor-alpha alters red blood cell kinetics and induces anemia in vivo
36. Prediction of response to erythropoietin treatment in chronic anemia of cancer